23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ARBUTUS BIOPHARMA CORP. › 2023-2024

ARBUTUS BIOPHARMA CORP. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 28, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 10Reported items
  • 113Asset managers, any item
  • 1,187Fund votes
  • May 22, 2024Meeting date

Results at a glance

Meeting of May 22, 2024: 9 items on ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 28, 2024: 2 approved · 7 passed (calculated).

Dissent

Notable dissent: 4 directors (13.6%, 10.6%, 10.2%, 10.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Two Seas Capital LP (13F, 4.1%, as of September 30, 2026) · Rubric Capital (13F, 1.7%, as of September 30, 2026)

Explore ARBUTUS BIOPHARMA CORP. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ARBUTUS BIOPHARMA CORP.

These tallies are ARBUTUS BIOPHARMA CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARBUTUS BIOPHARMA CORP. — official shareholder meeting results, meeting held May 22, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Frank Torti, M.D. 116,514,685---- 6,089,73824,915,140 95%Passed (calculated)—
Elect Director: Michael J. McElhaugh 110,465,378---- 12,139,04524,915,140 90%Passed (calculated)—
Elect Director: Daniel Burgess 110,133,889---- 12,470,53424,915,140 90%Passed (calculated)—
Elect Director: Richard C. Henriques 109,654,719---- 12,949,70424,915,140 89%Passed (calculated)—
Elect Director: Keith Manchester, M.D. 105,954,077---- 16,650,34624,915,140 86%Passed (calculated)—
Elect Director: James Meyers 110,186,534---- 12,417,88924,915,140 90%Passed (calculated)—
Elect Director: Melissa V. Rewolinski, Ph.D. 111,055,063---- 11,549,36024,915,140 91%Passed (calculated)—
3. To approve, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular 99,284,55713,548,3189,771,548 --24,915,140 88%Approved—
4. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 146,351,847648,515519,201 ---- 99.6%Approved—

Source: ARBUTUS BIOPHARMA CORP., Form 8-K, filed with the SEC on May 28, 2024 — read the filing on EDGAR.

How asset managers voted at the ARBUTUS BIOPHARMA CORP. 2023-2024 meeting

113 asset managers disclosed a vote on at least one ARBUTUS BIOPHARMA CORP. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ARBUTUS BIOPHARMA CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Daniel Burgess

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 110,133,889WITHHELD: 12,470,534
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Daniel Burgess

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Daniel Burgess”): 110,133,889 for, 12,470,534 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 18,194,797 for, 216,415 withheld.

FOR
FOR: 18,194,797WITHHOLD: 216,415
Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley3,557,5350 00For
Fidelity1,498,1930 084,361Mixed
Equitable572,3780 096,040Mixed
Charles Schwab339,2150 00For
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century125,4250 00For
Lincoln Financial103,0000 00For
Northern Trust63,2160 00For
John Hancock53,1320 00For
Pacific Life50,4530 00For
Voya44,9050 00For
Amplify ETF Trust43,2990 00For
Brighthouse41,6120 00For
ProShares32,5360 00For
Bridge Builder Trust30,5810 00For
Nationwide28,8940 00For
Principal Exchange-Traded Funds25,4000 00For
Invesco00 019,699Withhold
DWS19,5830 00For
AIG/SunAmerica18,3840 00For
SEI16,7000 00For
Principal14,6840 00For
Federated Hermes11,0330 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Elect Director: Frank Torti, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 116,514,685WITHHELD: 6,089,738
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Frank Torti, M.D.

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Frank Torti, M.D.”): 116,514,685 for, 6,089,738 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 18,402,088 for, 9,124 withheld.

FOR
FOR: 18,402,088WITHHOLD: 9,124
Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley3,557,5350 00For
Fidelity1,582,5540 00For
Equitable668,4180 00For
Charles Schwab339,2150 00For
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century125,4250 00For
Lincoln Financial103,0000 00For
Northern Trust63,2160 00For
John Hancock53,1320 00For
Pacific Life50,4530 00For
Voya44,9050 00For
Amplify ETF Trust43,2990 00For
Brighthouse41,6120 00For
ProShares32,5360 00For
Bridge Builder Trust30,5810 00For
Nationwide28,8940 00For
Principal Exchange-Traded Funds25,4000 00For
Invesco19,6990 00For
DWS19,5830 00For
AIG/SunAmerica18,3840 00For
SEI16,7000 00For
Principal14,6840 00For
Federated Hermes11,0330 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Elect Director: James Meyers

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 110,186,534WITHHELD: 12,417,889
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: James Meyers

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: James Meyers”): 110,186,534 for, 12,417,889 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 18,214,496 for, 196,716 withheld.

FOR
FOR: 18,214,496WITHHOLD: 196,716
Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley3,557,5350 00For
Fidelity1,498,1930 084,361Mixed
Equitable572,3780 096,040Mixed
Charles Schwab339,2150 00For
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century125,4250 00For
Lincoln Financial103,0000 00For
Northern Trust63,2160 00For
John Hancock53,1320 00For
Pacific Life50,4530 00For
Voya44,9050 00For
Amplify ETF Trust43,2990 00For
Brighthouse41,6120 00For
ProShares32,5360 00For
Bridge Builder Trust30,5810 00For
Nationwide28,8940 00For
Principal Exchange-Traded Funds25,4000 00For
Invesco19,6990 00For
DWS19,5830 00For
AIG/SunAmerica18,3840 00For
SEI16,7000 00For
Principal14,6840 00For
Federated Hermes11,0330 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Elect Director: Keith Manchester, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%
FOR: 105,954,077WITHHELD: 16,650,346
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Keith Manchester, M.D.

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Keith Manchester, M.D.”): 105,954,077 for, 16,650,346 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 17,391,946 for, 966,134 withheld, 53,132 abstained.

FOR
FOR: 17,391,946ABSTAIN: 53,132WITHHOLD: 966,134
Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley3,557,5350 00For
Fidelity1,498,1930 084,361Mixed
Equitable572,3780 096,040Mixed
Charles Schwab00 0339,215Withhold
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century125,4250 00For
Lincoln Financial00 0103,000Withhold
Northern Trust00 063,216Withhold
John Hancock00 53,1320Abstain
Pacific Life50,4530 00For
Voya00 044,905Withhold
Amplify ETF Trust43,2990 00For
Brighthouse00 041,612Withhold
ProShares00 032,536Withhold
Bridge Builder Trust30,5810 00For
Nationwide00 028,894Withhold
Principal Exchange-Traded Funds00 025,400Withhold
Invesco19,6990 00For
DWS00 019,583Withhold
AIG/SunAmerica00 018,384Withhold
SEI00 016,700Withhold
Principal00 014,684Withhold
Federated Hermes11,0330 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Elect Director: Melissa V. Rewolinski, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 111,055,063WITHHELD: 11,549,360
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Melissa V. Rewolinski, Ph.D.

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Melissa V. Rewolinski, Ph.D.”): 111,055,063 for, 11,549,360 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 18,411,212 for.

FOR
FOR: 18,411,212
Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley3,557,5350 00For
Fidelity1,582,5540 00For
Equitable668,4180 00For
Charles Schwab339,2150 00For
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century125,4250 00For
Lincoln Financial103,0000 00For
Northern Trust63,2160 00For
John Hancock53,1320 00For
Pacific Life50,4530 00For
Voya44,9050 00For
Amplify ETF Trust43,2990 00For
Brighthouse41,6120 00For
ProShares32,5360 00For
Bridge Builder Trust30,5810 00For
Nationwide28,8940 00For
Principal Exchange-Traded Funds25,4000 00For
Invesco19,6990 00For
DWS19,5830 00For
AIG/SunAmerica18,3840 00For
SEI16,7000 00For
Principal14,6840 00For
Federated Hermes11,0330 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Elect Director: Michael J. McElhaugh

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 110,465,378WITHHELD: 12,139,045
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Michael J. McElhaugh

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Michael J. McElhaugh”): 110,465,378 for, 12,139,045 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 18,411,212 for.

FOR
FOR: 18,411,212
Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley3,557,5350 00For
Fidelity1,582,5540 00For
Equitable668,4180 00For
Charles Schwab339,2150 00For
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century125,4250 00For
Lincoln Financial103,0000 00For
Northern Trust63,2160 00For
John Hancock53,1320 00For
Pacific Life50,4530 00For
Voya44,9050 00For
Amplify ETF Trust43,2990 00For
Brighthouse41,6120 00For
ProShares32,5360 00For
Bridge Builder Trust30,5810 00For
Nationwide28,8940 00For
Principal Exchange-Traded Funds25,4000 00For
Invesco19,6990 00For
DWS19,5830 00For
AIG/SunAmerica18,3840 00For
SEI16,7000 00For
Principal14,6840 00For
Federated Hermes11,0330 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Elect Director: Richard C. Henriques

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 109,654,719WITHHELD: 12,949,704
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Richard C. Henriques

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Richard C. Henriques”): 109,654,719 for, 12,949,704 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 18,411,212 for.

FOR
FOR: 18,411,212
Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley3,557,5350 00For
Fidelity1,582,5540 00For
Equitable668,4180 00For
Charles Schwab339,2150 00For
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century125,4250 00For
Lincoln Financial103,0000 00For
Northern Trust63,2160 00For
John Hancock53,1320 00For
Pacific Life50,4530 00For
Voya44,9050 00For
Amplify ETF Trust43,2990 00For
Brighthouse41,6120 00For
ProShares32,5360 00For
Bridge Builder Trust30,5810 00For
Nationwide28,8940 00For
Principal Exchange-Traded Funds25,4000 00For
Invesco19,6990 00For
DWS19,5830 00For
AIG/SunAmerica18,3840 00For
SEI16,7000 00For
Principal14,6840 00For
Federated Hermes11,0330 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and…

No official matchCOMPENSATION

Combines 3 wordings of this item as funds reported it.

99.3% of fund votes cast · no official result

FOR
Details: description as filed, votes by 35 asset managers

Description as filed by funds: To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended, to (a) increase the aggregate number of common shares authorized for issuance thereunder by 9,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 9,500,000 common shares;

The 35 asset managers below reported 18,274,527 for, 136,685 against, 64,726 mixed. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 18,274,527AGAINST: 136,685MIXED: 64,726
Largest asset managers voting on “To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplem” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley3,557,5350 00For
Fidelity1,582,5540 00For
Equitable668,4180 00For
Charles Schwab339,2150 00For
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century0125,425 00Against
Lincoln Financial103,0000 00For
Saba Capital Income & Opportunities Fund00 00--
Northern Trust63,2160 00For
John Hancock53,1320 00For
Pacific Life50,4530 00For
Voya44,9050 00For
Amplify ETF Trust43,2990 00For
Brighthouse41,6120 00For
ProShares32,5360 00For
Bridge Builder Trust30,5810 00For
Nationwide28,8940 00For
Principal Exchange-Traded Funds25,4000 00For
Invesco19,6990 00For
DWS19,5830 00For
AIG/SunAmerica18,3840 00For
SEI16,7000 00For
Principal14,6840 00For

Showing the 25 largest of 35 asset managers. All 35 are in the interactive database (link above).

To approve, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

88% Approved · of votes cast

FOR 88%
FOR: 99,284,557AGAINST: 13,548,318
Details: description as filed, official tally, votes by 113 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“3. To approve, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular”): 99,284,557 for, 13,548,318 against — passed, per its Form 8-K filed May 28, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 35 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in ” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley5,6030 3,551,9320Abstain
Fidelity1,582,5540 00For
Equitable316,1210 352,2970Mixed
Charles Schwab339,2150 00For
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century0125,425 00Against
Lincoln Financial103,0000 00For
Saba Capital Income & Opportunities Fund00 00--
Northern Trust63,2160 00For
John Hancock53,1320 00For
Pacific Life50,4530 00For
Voya44,9050 00For
Amplify ETF Trust43,2990 00For
Brighthouse41,6120 00For
ProShares32,5360 00For
Bridge Builder Trust30,5810 00For
Nationwide28,8940 00For
Principal Exchange-Traded Funds25,4000 00For
Invesco19,6990 00For
DWS19,5830 00For
AIG/SunAmerica18,3840 00For
SEI16,7000 00For
Principal14,6840 00For

Fund voting reports, all 35 managers: 14,372,434 for, 134,549 against, 3,904,229 abstained, 64,726 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 91 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in ” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Whitefort Capital Management, LP12,862,1520 00For
Morgan Stanley00 8,070,1710Abstain
Two Seas Capital LP07,463,977 00Against
BlackRock4,942,2570 00For
Woodline Partners LP3,249,6730 00For
Hudson Bay Capital Management LP3,028,2350 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.3,000,0000 00For
GEODE CAPITAL MANAGEMENT, LLC1,641,2750 00For
State Street1,497,5220 00For
Centiva Capital, LP1,322,8270 00For
Citadel1,083,5220 00For
Northern Trust942,361233 00For
Corbin Capital Partners, L.P.847,2310 00For
Wellington381,1400 00For
BOOTHBAY FUND MANAGEMENT, LLC352,2550 00For
Charles Schwab339,2150 00For
MELLON INVESTMENTS Corp298,2600 00For
KENNEDY CAPITAL MANAGEMENT LLC285,9240 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC185,7210 00For
Vanguard152,4660 00For
American Century0125,425 00Against
AllianceBernstein96,0400 00For
Fidelity95,7580 00For
Clear Harbor Asset Management, LLC78,7610 00For
RBC Dominion Securities Inc.66,8710 00For

Institutional-manager reports, all 91 managers: 37,432,706 for, 7,661,265 against, 8,078,114 abstained. Showing the 25 largest; every one is in the interactive database (link above).

To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 146,351,847AGAINST: 648,515
Details: description as filed, official tally, votes by 35 asset managers

Description as filed by funds: To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“4. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 146,351,847 for, 648,515 against — passed, per its Form 8-K filed May 28, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(4) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 35 asset managers below reported 18,411,212 for, 64,726 mixed.

FOR
FOR: 18,411,212MIXED: 64,726
Largest asset managers voting on “To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the f” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,797,9520 00For
BlackRock5,441,1670 00For
Morgan Stanley3,557,5350 00For
Fidelity1,582,5540 00For
Equitable668,4180 00For
Charles Schwab339,2150 00For
QUANTITATIVE MASTER SERIES LLC236,1610 00For
American Century125,4250 00For
Lincoln Financial103,0000 00For
Saba Capital Income & Opportunities Fund00 00--
Northern Trust63,2160 00For
John Hancock53,1320 00For
Pacific Life50,4530 00For
Voya44,9050 00For
Amplify ETF Trust43,2990 00For
Brighthouse41,6120 00For
ProShares32,5360 00For
Bridge Builder Trust30,5810 00For
Nationwide28,8940 00For
Principal Exchange-Traded Funds25,4000 00For
Invesco19,6990 00For
DWS19,5830 00For
AIG/SunAmerica18,3840 00For
SEI16,7000 00For
Principal14,6840 00For

Showing the 25 largest of 35 asset managers. All 35 are in the interactive database (link above).

Largest ARBUTUS BIOPHARMA CORP. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 188,717,409 shares outstanding at the time of that meeting.

Fund voting reports: top ARBUTUS BIOPHARMA CORP. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 3.07%
2BlackRock 2.88%
3Morgan Stanley 1.89%
4Fidelity 0.84%
5Equitable 0.35%
6Charles Schwab 0.18%
7QUANTITATIVE MASTER SERIES LLC 0.13%
8American Century 0.07%
9Lincoln Financial 0.05%
10Saba Capital Income & Opportunities Fund 0.03%
Institutional-manager reports: top ARBUTUS BIOPHARMA CORP. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1Whitefort Capital Management, LP 6.82%
2Morgan Stanley 4.28%
3Two Seas Capital LP 3.96%
4BlackRock 2.62%
5Woodline Partners LP 1.72%
6Hudson Bay Capital Management LP 1.60%
7ADAGE CAPITAL PARTNERS GP, L.L.C. 1.59%
8GEODE CAPITAL MANAGEMENT, LLC 0.87%
9State Street 0.79%
10Centiva Capital, LP 0.70%

Reported ARBUTUS BIOPHARMA CORP. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ARBUTUS BIOPHARMA CORP. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Roivant38,847,462 20.58%Proxy statement (DEF 14A), proxy filed April 10, 2024
Morgan Stanley24,450,612 12.96%Form 13F, quarter ended March 31, 2024
Whitefort Capital Management, LP13,197,062 6.99%Schedule 13G, filed February 14, 2024
Blackrock, Inc.10,390,300 5.51%Proxy statement (DEF 14A), proxy filed April 10, 2024
Two Seas Capital LP9,041,927 4.79%Proxy statement (DEF 14A), proxy filed April 10, 2024
Vanguard Group8,991,082 4.76%Form 13F, quarter ended March 31, 2024
Michael J. Sofia, Ph.D.2,824,940 1.50%Proxy statement (DEF 14A), proxy filed April 10, 2024
State Street2,611,890 1.38%Form 13F, quarter ended March 31, 2024
Michael J. McElhaugh2,223,891 1.18%Proxy statement (DEF 14A), proxy filed April 10, 2024
Citadel Advisors2,195,604 1.16%Form 13F, quarter ended March 31, 2024

Percentages above are of 188,717,409 shares outstanding, as reported by ARBUTUS BIOPHARMA CORP. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ARBUTUS BIOPHARMA CORP.'s shareholder meeting held May 22, 2024, in the 2023-2024 proxy season, 113 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,187 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — ARBUTUS BIOPHARMA CORP.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ARBUTUS BIOPHARMA CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 28, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARBUTUS BIOPHARMA CORP.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ARBUTUS BIOPHARMA CORP. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ARBUTUS BIOPHARMA (ABUS) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/arbutus-biopharma-corp/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.